T0	Participants 4 12	European
T1	Participants 61 87	pre-hospital thrombolysis.
T2	Participants 123 168	patients with suspected myocardial infarction
T3	Participants 647 692	patients with suspected myocardial infarction
T4	Participants 763 1087	total of 5469 patients in 16 countries were randomised by 198 mobile emergency units to receive either pre-hospital treatment with anistreplase, the thrombolytic agent used, followed by placebo after hospital admission (pre-hospital group; 2750 patients), or placebo followed by anistreplase (hospital group; 2719 patients).
T5	Participants 1654 1699	patients with suspected myocardial infarction